Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #923

    Er der forresten nogen, der har set SH-tal?

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #924

      Det er vel epco Winkel omtaler. Jeg tænkte hvis GEN1046 kunne nå markedet 2023...

      1 Reply Last reply
      0
      • StockBullS Offline
        StockBullS Offline
        StockBull
        wrote on sidst redigeret af
        #925

        Lader til det er 450 mil kr JNJ tilbageholder p.g.a Halozyme royalty sagen for 2021

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #926

          Sorry solsen, det er mig der roder

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #927

            Den står 2-2. Novod og Barclays ned. MS og DDB op.

            1 Reply Last reply
            0
            • D Offline
              D Offline
              deleted-user
              wrote on sidst redigeret af
              #928

              Børen - "Gen­mab-kurs­mål sæn­kes på stri­be", det må således være den halve sandhed hvis den står 2-2

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #929

                Fint at GS. De er ved at bygge en større position op i Genmab.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #930

                  GS har så vidt jeg kan se +3% af Genmab aktier.

                  1 Reply Last reply
                  0
                  • JørgenVarnæsJ Offline
                    JørgenVarnæsJ Offline
                    JørgenVarnæs
                    wrote on sidst redigeret af
                    #931

                    GS har ikke ligefrem for vane at have et target, der ligger nord for den aktuelle kurs. Det er måske den reelle grund til deres revision...

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #932

                      Omkring timing af GEN1046, så er det nærmeste vi kom i går vist JvdW svar til Verdult - https://www.fool.com/earnings/call-transcripts/2021/02/23/genmab-as-gmab-q4-2020-earnings-call-transcript/

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #933

                        Her siger han, at man forventer data fra expansion cohorts, men ikke meget andet

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #934

                          Jyske Banks anbefaling: https://www.proinvestor.com/investornyt/672464/genmab-jyske-bank-anbefaling-haeves-til-kob-fra-hold

                          1 Reply Last reply
                          0
                          • C Offline
                            C Offline
                            Connecting
                            wrote on sidst redigeret af
                            #935

                            Sydbank analyser post regnskab:

                            1 Reply Last reply
                            0
                            • C Offline
                              C Offline
                              Connecting
                              wrote on sidst redigeret af
                              #936

                              https://markets.sydbank.dk/PublicationsWebHandler/Default.aspx?ID=0042061-076403

                              1 Reply Last reply
                              0
                              • JørgenVarnæsJ Offline
                                JørgenVarnæsJ Offline
                                JørgenVarnæs
                                wrote on sidst redigeret af
                                #937

                                Det ser ud til, at 2021 bliver anderledes - nu kan vi se frem til masser af read-outs og ikke kun sidde og kigge på recepttal for dara. Det bliver lidt mere som de gode gamle dage

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #938

                                  yes, Genmab was always blamed to be a 'one trick pony'. So now that that is changing, we suddenly invest too much...

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #939

                                    I mean, we knew the products in the pipeline, so we knew how much investment will have to go into that. So for me, higher investmenst now means bringing investments forward. So my only conclusion can be that the majority of the analysts think that Genmab is going to fast I guess?

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #940

                                      It
                                      is why I asked
                                      @troldmanden yesterday, ‘if they would delay that 1bn for a year, so that cost would be in line with analysts expectations, would you feel better?’ Personally, I don’t understand that…

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #941

                                        This is one of those delightful moments, where we can put our money where out mouths are - Through the collaborations GEN has mitigated the risks of not being able to handle scale and speed in these large programs - now GEN must put up the money to make these things happen. That will hopefully be worth the investment

                                        1 Reply Last reply
                                        0
                                        • JørgenVarnæsJ Offline
                                          JørgenVarnæsJ Offline
                                          JørgenVarnæs
                                          wrote on sidst redigeret af
                                          #942

                                          If analysts just see elevated costs - fine by me

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger